GlassScriptPhysician profile
Czerina Ottes
NPI 1780281618
$2,780.20
in general payments reported to CMS, 2019-2025
23 companies · $773 in 2025
The $773 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.74 · 2022: $488 · 2023: $742 · 2024: $747 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,262.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $822.48 | 2021-2025 | |
| Lilly USA, LLC | $521.94 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $314.96 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $193.16 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.49 | 2022-2025 | Jardiance |
| Amgen INC. | $122.32 | 2022-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $108.49 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $88.29 | 2022-2025 | Airsupra, Farxiga |
| Axsome Therapeutics, INC. | $62.39 | 2024 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $50.31 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.73 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $36.94 | 2023 | Belsomra, Vaxneuvance, M-M-R II |
| Exact Sciences Corporation | $36.48 | 2024-2025 | Cologuard Collection Kit |
| Tris Pharma INC | $36.23 | 2024-2025 | Dyanavel Xr |
| Phathom Pharmaceuticals, INC. | $35.32 | 2024-2025 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $25.73 | 2024 | Paradise Renal Denervation System |
| Ironwood Pharmaceuticals, INC | $24.09 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.66 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $21.74 | 2023 | Livalo |
| Novartis Pharmaceuticals Corporation | $19.29 | 2024 | |
| Ironshore Pharmaceuticals INC. | $18.97 | 2024 | |
| Nevro Corp. | $17.33 | 2023 | Senza |
| E.R. Squibb & Sons, L.L.C. | $14.86 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Czerina Ottes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.